ArticleIJID regions2023
Incidence of COVID-19 in cancer patients in a teaching hospital faculty of medicine, in Medan, Indonesia.
Article in IJID regions, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to determine the incidence of COVID-19 in cancer patients in the Teaching Hospital Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia. Methods: This descriptive study was conducted at H. Adam Malik Hospital and USU General Hospital, Medan, from March 2020 to August 2021. The main inclusion criteria for the participants were COVID-19 and confirmed cancer. A total sampling technique was used. Results: Among the 3308 COVID-19 patients studied, the mean age was 44 years, ranging from 1 day to 92 years. Male participants were slightly more prevalent (51.8% vs 48.2%). Twenty-five of these patients (0.75%) had both COVID-19 and cancer, and thus met the inclusion criteria. The most common types of cancer were leukemia (20.0%), breast cancer (20.0%), ovarian cancer (16.0%), lymphoma (8.0%), and osteosarcoma (8.0%). The proportions of patients with mild, moderate, and severe degrees of COVID-19 where 48.0%, 24.0%, and 28.0%, respectively. Seven patients required intensive care, and five died. Conclusion: The incidence of COVID-19 in patients with cancer was relatively low. Nevertheless, almost a third of cancer patients with COVID-19 developed severe disease and had poor prognoses. Vaccination among cancer patients is important to protect them from poor outcomes if exposed to COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.